Two digital health startups to champion the next generation of primary care in Kenya for a better patient journey
TAIPEI, Taiwan and NAIROBI, Kenya , March 16, 2021 (GLOBE NEWSWIRE) -- iXensor Co., Ltd. (6734.TWO)
iXensor, the pioneer of mobile health, partners with Ilara Health, the health-tech company, to solve the lack of affordable medical testing for non-communicable diseases in Kenya's primary care settings by providing integrated point-of-care diagnostics to more than a hundred of small clinics.
"There is an acute need in Kenya and across the continent for early detection of metabolic diseases. With iXensor's PixoTest, our partner facilities can do this. The PixoTest POCT System is affordable, portable, and its data integration feature allows us to use it for remote patient management, ensuring that patients can receive the highest quality of care when managing their conditions," said Mr. Emilian Popa, the CEO of Ilara Health.
More than 70% of the patients seeking medical care from small clinics require testing, and they are usually referred to larger centralized clinical centers. However, the time and cost of visiting large medical centers are enormous barriers to the majority.
By connecting iXensor’s palm-size PixoTest diagnostics to Ilara Health's Mbali Health platform, the two startups provide rapid blood testing and digital communication services to patients directly through clinics. Dr. Mwihurih Githinji commented, "Because of lifestyle changes, NCDs are becoming bigger healthcare burdens with diabetes and hypertension taking the lead. If I am able to identify diabetes or pre-diabetics earlier, then the management will be much faster."
Dr. Carson Chen, the CEO of iXensor addressed that "Being able to communicate the blood test results directly through patients’ mobile phones is a great benefit we are empowering the healthcare professionals on the front line. Together with Ilara Health, we will continue to expand the access to timely and quality medical testing for more patients in need of better care.”
About iXensor
iXensor, the pioneer of mobile health, turns smartphones into lab-grade mobile medical diagnostics. In 2017, iXensor introduced the PixoTest® Blood Glucose Monitoring System as the world's first US FDA-approved smartphone camera-based blood test. Based on the PixoTech® platform, iXensor has ventured into at-home self-testing and clinical diagnostics across infectious diseases, women's health, and cardiovascular diseases.
Media Contact
Spokesperson: Patrick Liao
Company Website: www.ixensor.com
Email: pr@ixensor.com
Phone: +886-2-8751-1335 ext.205
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d7fd3198-7a7b-4a9c-88eb-f3e27dd94060
About GlobeNewswire
GlobeNewswireGlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Immunicum Announces Presentations at Upcoming Scientific Conferences in April and May19.4.2021 08:00:00 CEST | Press release
Press Release 19 April 2021 Immunicum Announces Presentations at Upcoming Scientific Conferences in April and May Immunicum AB (publ) today announced that it will participate and deliver multiple presentations featuring its proprietary Phase II clinical candidates, immune primer ilixadencel and cancer relapse vaccine DCP-001, at the following upcoming scientific conferences: Neoantigen Summit Europe, April 20 – 22, 2021 Alex Karlsson-Parra, Chief Scientific Officer at Immunicum, will make an oral presentation on “Harnessing the immune-priming function of allogeneic dendritic cells in neoantigen-based vaccines”, on Wednesday, April 21st at 2:45 pm CET / 8:45 am ET. Cancer Immunotherapy (CIMT) Annual Meeting, May 10 – 12, 2021. Alex Karlsson-Parra will deliver an oral presentation on “Combining intratumoral administration of inflammatory allogeneic DCs with systemic anti-CTLA-4 treatment leads to tumor eradication and is associated with peripheral expansion of CD8+ effector cells with a
Intervest starts construction works at Herentals Green Logistics19.4.2021 08:00:00 CEST | Press release
#TeamIntervest gives concrete shape to a sustainable cluster of 45.000 m² of offices and logistics. Attachment Development project Herentals
Immunicum tillkännager presentationer vid kommande vetenskapliga möten i april och maj19.4.2021 08:00:00 CEST | Pressemelding
Pressrelease 19 april 2021 Immunicum tillkännager presentationer vid kommande vetenskapliga möten i april och maj Immunicum AB (publ) meddelade idag att bolaget kommer att delta och göra ett flertal presentioner gällande sina två program i klinisk fas II-utveckling, immunprimern ilixadencel och canceråterfallsvaccinet DCP-001 vid nedanstående vetenskapliga möten: Neoantigen Summit Europe, 20 – 22 april, 2021 Alex Karlsson-Parra, Chief Scientific Officer, Immunicum håller ett anförande på temat ” “Harnessing the immune-priming function of allogeneic dendritic cells in neoantigen-based vaccines”, onsdagen den 21 april kl. 14.45 CET/8.45 ET. Cancer Immunotherapy (CIMT) Annual Meeting, 10-12 maj, 2021 Alex Karlsson-Parra, Chief Scientific Officer, Immunicum håller ett anförande på temat “Combining intratumoral administration of inflammatory allogeneic DCs with systemic anti-CTLA-4 treatment leads to tumor eradication and is associated with peripheral expansion of CD8+ effector cells with a
ABN AMRO accepted settlement offer in the anti-money laundering investigation in the Netherlands19.4.2021 07:30:00 CEST | Press release
ABN AMRO accepted settlement offer in the anti-money laundering investigation in the Netherlands Today ABN AMRO Bank N.V. (ABN AMRO) announced that it has accepted a settlement offer from the Dutch Public Prosecution Service (DPPS) in connection with the previously announced investigation by the DPPS into ABN AMRO's compliance with its obligations under the Dutch Anti-Money Laundering and Counter Terrorism Financing Act (Wet ter voorkoming van witwassenen financiering van terrorisme, AML/CTF Act) between 2014 and 2020. As part of this settlement, ABN AMRO will pay EUR 480 million. ABN AMRO fully cooperated with the DPPS throughout the investigation. Based on the investigation, the DPPS identified serious shortcomings in ABN AMRO's processes to combat money laundering in the Netherlands, such as the client acceptance, transaction monitoring and client exit processes (the so-called 'Client Life Cycle' processes) in the period between 2014 and 2020, as a result of which, in certain instan
Nyxoah Announces Submission of Draft Registration Statement For Proposed Public Listing in the United States19.4.2021 07:02:32 CEST | Press release
REGULATED INFORMATION INSIDE INFORMATION Nyxoah Announces Submission of Draft Registration Statement For Proposed Public Listing in the United States Mont-Saint-Guibert, Belgium – 19 April 2021 – Nyxoah SA (Euronext Brussels: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that it has confidentially submitted a draft Registration Statement on Form F-1 to the Securities and Exchange Commission (the "SEC") relating to the proposed public offering of its ordinary shares in the United States. The number of ordinary shares to be offered and the price for the proposed offering have not yet been determined. The public offering is expected to take place after the SEC completes its review process, subject to market and other conditions. This announcement is being made pursuant to, and in accordance with, Rule 135 under the Securities Act of 1933, as am
Millicom signs agreements to conclude Africa divestiture program19.4.2021 06:05:00 CEST | Press release
Millicomsigns agreements to conclude Africa divestiture program Luxembourg,April19, 2021 – Millicom International Cellular S.A. (“Millicom”) announces that it has signed agreements for the sale of its operations in Tanzania and for its stake in the AirtelTigo joint venture in Ghana. Once closed, the transactions will complete Millicom’s multi-year plan to divest its African operations and focus on its Latin America markets. In Tanzania, Millicom has agreed to sell its entire operations to a consortium led by Axian, a pan-African group that was part of the consortium that acquired Millicom’s operations in Senegal in 2018. In Ghana, Millicom along with its joint venture partner, Bharti Airtel Limited, have signed a definitive agreement for the transfer of AirtelTigo to the Government of Ghana. Millicom will take a $25 million charge as a result of this agreement. Millicom CEO, Mauricio Ramos, commented: “Today Tigo is a leading provider of broadband services to consumers, businesses and
Nokia to deploy indoor 5G small cells solutions with LG Uplus in South Korea19.4.2021 03:00:00 CEST | Press release
Press Release Nokia to deploy indoor 5G small cells solutions with LG Uplus in South Korea Nokia will expand and enhance LG Uplus’ 5G network, enabling seamless 5G connectivity between indoor and outdoor locationsLG Uplus will use Nokia’s AirScale indoor solution which can be deployed flexibly and upgraded easily The deal continues the long-standing partnership between the two companies 19 April 2021 Espoo, Finland – Nokia today announced an agreement with LG Uplus to expand 5G coverage by installing new equipment from Nokia’s comprehensive AirScale portfolio across the country, enabling seamless 5G indoor and outdoor connectivity. The dealis expected to accommodate future network expansion and will further deepen the partnership between the two companies, which have already collaborated on LTE, 5G and digital projects. Being the first deployment of its kind in South Korea, Nokia will install its cost-effective, next-generation small cell AirScale Indoor (ASiR) systems in a range of in